Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $193 from $157 and keeps an Overweight rating on the shares. The firm notes Auvelity/Sunosi sales in Q4 2025 came in above consensus, which it thinks will continue to support positive momentum in the stock. Wells updates its ADA probability of success to 90% from 75% given the FDA granted a priority review.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth
- Buy Rating on Axsome Therapeutics Backed by Strong Auvelity and Sunosi Outperformance Despite Slower Symbravo Ramp
- Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth
- Axsome Therapeutics reports preliminary Q4 revenue $196M, consensus $187.02M
- Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley